Teva Continues Divestitures To Close Allergan Deal With Product Sale To Impax
This article was originally published in The Pink Sheet Daily
Executive Summary
Impax will gain 15 approved generics and three pipeline assets, which will help offset lower revenues of two of its existing top-sellers.
You may also be interested in...
Impax CEO’s Strategy: Aggressive BD, Restructure R&D And Cut Costs
Since Impax Laboratories’ CEO Wilkinson took the helm in April, the company has completed several significant deals and most recently restructured R&D to deliver savings, but a successful turnaround will require resolving outstanding manufacturing issues.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.